AZN.L: AstraZeneca PLC Stock Live Price Graph
About the company
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Company profile
Market News & Analysis
Target Price
No analyst target price data is available for this instrument.
Dividend History
Cash dividends
| Payment | Gross / share | Net / share | Yield | Per 1,000 TRY |
|---|---|---|---|---|
| - | $159.5 | $159.5 | 1.54% | - |
| - | $76.7 | $76.7 | 2.23% | - |
| - | $168 | $168 | 2.12% | - |
| - | $60.8151 | $60.8151 | 1.46% | - |
| - | $123.2533 | $123.2533 | 1.79% | - |
| - | $56.5353 | $56.5353 | 1.72% | - |
| - | $135.3015 | $135.3015 | 1.77% | - |
| - | $76.4 | $76.4 | 1.63% | - |
| - | $108.0102 | $108.0102 | 1.80% | - |
| - | $46.8166 | $46.8166 | 1.74% | - |
| - | $97.9955 | $97.9955 | 2.16% | - |
| - | $53.2557 | $53.2557 | 1.95% | - |
| - | $113.7157 | $113.7157 | 2.42% | - |
| - | $59.3255 | $59.3255 | 2.35% | - |
| - | $110.8218 | $110.8218 | 2.67% | - |
| - | $53.2862 | $53.2862 | 2.45% | - |
| - | $95.2813 | $95.2813 | 3.15% | - |
| - | $53.0537 | $53.0537 | 3.92% | - |
| - | $120.509 | $120.509 | 3.84% | - |
| - | $53.0307 | $53.0307 | 2.80% | - |
| - | $91.5871 | $91.5871 | 3.11% | - |
| - | $36.8401 | $36.8401 | 2.76% | - |
| - | $81.071 | $81.071 | 2.55% | - |
| - | $31.7581 | $31.7581 | 2.48% | - |
| - | $70.0952 | $70.0952 | 2.71% | - |
| - | $37.9778 | $37.9778 | 3.56% | - |
| - | $77.5743 | $77.5743 | 3.89% | - |
| - | $37.1119 | $37.1119 | 3.83% | - |
| - | $78.3088 | $78.3088 | 3.80% | - |
| - | $31.7881 | $31.7881 | 3.74% | - |
| - | $72.2935 | $72.2935 | 3.41% | - |
| - | $28.2149 | $28.2149 | 2.94% | - |
| - | $66.907 | $66.907 | 3.13% | - |
| - | $21.4724 | $21.4724 | 3.37% | - |
| - | $71.425 | $71.425 | 3.27% | - |
| - | $14.3815 | $14.3815 | 1.93% | - |
| - | $34.6689 | $34.6689 | 2.33% | - |
| - | $12.498 | $12.498 | 1.77% | - |
| - | $32.079 | $32.079 | 1.56% | - |
| - | $14.0248 | $14.0248 | 1.36% | - |
| - | $29.7064 | $29.7064 | 1.58% | - |
| - | $12.1214 | $12.1214 | 1.18% | - |
| - | $18.3613 | $18.3613 | 1.28% | - |
| - | $8.7234 | $8.7234 | 1.03% | - |
| - | $15.6386 | $15.6386 | 1.00% | - |
| - | $9.7697 | $9.7697 | 1.11% | - |
| - | $17.9271 | $17.9271 | 1.28% | - |
| - | $9.6432 | $9.6432 | 1.68% | - |
| - | $23.238 | $23.238 | 0.99% | - |
| - | $11.1232 | $11.1232 | 0.99% | - |
| - | $21.7376 | $21.7376 | 1.03% | - |
| - | $10.6593 | $10.6593 | 0.91% | - |
| - | $18.4156 | $18.4156 | 1.24% | - |
| - | $8.7819 | $8.7819 | 1.04% | - |
| - | $17.4322 | $17.4322 | 0.93% | - |
| - | $8.3297 | $8.3297 | 1.04% | - |
| - | $14.954 | $14.954 | 0.92% | - |
| - | $8.414 | $8.414 | 1.23% | - |
| - | $14.0526 | $14.0526 | 1.26% | - |
| - | $8.0243 | $8.0243 | 1.39% | - |
| - | $12.877 | $12.877 | 1.50% | - |
| - | $7.1793 | $7.1793 | 1.72% | - |
| - | $11.1846 | $11.1846 | 0.02% | - |
| - | $6.8536 | $6.8536 | 0.02% | - |
| - | $11.3968 | $11.3968 | 0.03% | - |
| - | $6.9447 | $6.9447 | 0.01% | - |
What Is AZN.L? Live AZN.L Prices and Analysis
AZN.L, the ticker symbol for AstraZeneca PLC, is a globally renowned biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. As a major player in the healthcare sector, AstraZeneca has made significant contributions in areas such as oncology, cardiovascular, renal, and respiratory diseases, making it a focal point for investors looking to tap into the pharmaceutical industry's potential for growth and innovation.
Investors closely follow AZN.L due to its strong market presence, robust pipeline of drugs, and consistent performance in earnings and dividends. With healthcare being an essential service, companies like AstraZeneca not only play a crucial role in improving global health outcomes but also represent a stable investment opportunity, particularly in uncertain economic times.
Market Context for AZN.L
The stock market is influenced by various factors, including international trading dynamics, currency fluctuations, and sector-specific volatility. AstraZeneca operates in a global market, where its stock performance can be affected by international regulatory approvals, competition from generic drugs, and the overall demand for healthcare solutions. The pricing of AZN.L is typically denominated in British pounds, and fluctuations in exchange rates can impact the stock's attractiveness to foreign investors.
Why Do AZN.L Prices Rise or Fall?
The price of AZN.L shares can be influenced by a multitude of factors that investors should consider when evaluating the stock. Understanding these dynamics is crucial for making informed investment decisions.
- Drug approval news and clinical trial results
- Changes in healthcare regulations and policies
- Market competition and patent expirations
- Earnings reports and revenue forecasts
- Global health trends and disease outbreaks
- Investor sentiment and market speculation
- Macroeconomic factors, such as interest rates and inflation
- Mergers and acquisitions within the pharmaceutical sector
In summary, AZN.L's stock price is subject to a complex interplay of internal and external factors, which can lead to significant price movements. Keeping abreast of these influences is essential for investors looking to capitalize on AstraZeneca's potential.
Why Is Live AZN.L Price Tracking Important?
Tracking the live price of AZN.L is vital for investors for several reasons. It allows them to make timely decisions based on the most current market data, which can be crucial in the fast-paced world of stock trading.
- Enables quick reaction to market changes
- Helps in identifying trends and patterns
- Facilitates better entry and exit points for trades
- Assists in evaluating the effectiveness of investment strategies
- Provides insights into market sentiment and investor behavior
What Should You Consider When Trading / Investing in AZN.L?
When considering an investment in AZN.L, it is essential to evaluate various factors that could impact the stock's performance. Investors should be aware of the inherent risks associated with the pharmaceutical sector, including regulatory hurdles and competition. Additionally, macroeconomic data such as GDP growth, unemployment rates, and inflation can influence market sentiment and stock prices.
Volatility is another crucial aspect to monitor. While AstraZeneca has shown resilience, external factors can lead to sudden price fluctuations, which may not align with the company's underlying fundamentals. Therefore, a thorough analysis is vital for anyone looking to trade or invest in AZN.L.
What Can You Find on the Investvio AZN.L Page?
- Live price updates and historical data
- Comprehensive stock charts for trend analysis
- Technical analysis tools for informed trading
- Latest news and announcements related to AstraZeneca
- Analyst ratings and earnings forecasts
In conclusion, the AZN.L stock represents a compelling investment opportunity within the biopharmaceutical sector. By leveraging the resources available on the Investvio AZN.L page, investors can stay informed and make strategic decisions that align with their financial goals. Understanding the nuances of AZN.L will empower investors to navigate this dynamic market effectively.